RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Iggs, it's not surprising that you could project 'battle of egos' on to that. But this has to do with facts--the fact that to demonstrate an impact upon progression, one would need to follow several thousand patients for several years to document the impact of a medication. At the cost of...at least $200-300 million? No one has ever carried out such a trial, so no one knows how long it would take. It's just such an absurdity to suggest that Cortex should have done that instead of its 24pt ADHD trial.....

Back to polishing brass and rearranging deck chairs.

NeuroInvestment